Another successful case study is the use of polygenic risk scores to predict the benefits of chemotherapy for early breast cancer patients with estrogen receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative pathology. Here, ERBB2 is linked to breast carcinoma.